Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | ICMT | O60725 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523884 | 0.87 | USP2 (0.48) | ARUSP2MAPTSLC6A4SLC6A2 | |
| SCHEMBL5649109 | 0.86 | ABL1 (0.47) | ARPPARDPPARAICMT | |
| SCHEMBL17815716 | 0.80 | ACHE (0.53) | USP2MAPTPDE4B | |
| SCHEMBL11749561 | 0.79 | AR (0.50) | ARUSP2MAPTSLC6A4SLC6A2 | |
| SCHEMBL19473156 | 0.79 | HPGD (0.49) | SLC6A4SLC6A2SLC6A3HTR3AKCNH2 | |
| SCHEMBL21501064 | 0.79 | AR (0.60) | ARUSP2MAPTSLC6A4SLC6A2 | |
| SCHEMBL10187116 | 0.79 | GAA (0.57) | ARUSP2MAPTPDE4BPDE4A | |
| SCHEMBL524008 | 0.79 | CHRNB4 (0.66) | SLC6A4 | |
| SCHEMBL6944897 | 0.78 | TRPV4 (0.56) | ARUSP2MAPTSLC6A4PDE4B | |
| SCHEMBL25720711 | 0.77 | PDE4B (0.42) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1080069-B1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6384080-B1 | TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| EP-1080069-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999054284-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | PDE3A, PDE2A, PDE5A | AR 2696/4885USP2 2138/4885MAPT 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.